Log In | Learn More What’s included? An experimental treatment aimed at helping people with severe peanut allergy scored a clinical win Tuesday, putting it in line to possibly become the first drug to provide meaningful protection against accidental exposure.Based on the positive results, Aimmune Therapeutics expects to seek U.S. approval for its preventative peanut allergy therapy by the end of the year, with a European filing in 2019, the company said. By Adam Feuerstein Feb. 20, 2018 Reprints Adam Feuerstein What is it? Biotech Senior Writer, Biotech Adam is STAT’s national biotech columnist, reporting on the intersection of biotech and Wall Street. He’s also a co-host of “The Readout LOUD” podcast. @adamfeuerstein Peanut allergy therapy scores trial win, putting it in line to possibly become first protective treatment Daily reporting and analysis The most comprehensive industry coverage from a powerhouse team of reporters Subscriber-only newsletters Daily newsletters to brief you on the most important industry news of the day STAT+ Conversations Weekly opportunities to engage with our reporters and leading industry experts in live video conversations Exclusive industry events Premium access to subscriber-only networking events around the country The best reporters in the industry The most trusted and well-connected newsroom in the health care industry And much more Exclusive interviews with industry leaders, profiles, and premium tools, like our CRISPR Trackr. Tags biotechdrug developmentFDA About the Author Reprints GET STARTED [email protected] Unlock this article by subscribing to STAT+ and enjoy your first 30 days free! GET STARTED APStock STAT+ is STAT’s premium subscription service for in-depth biotech, pharma, policy, and life science coverage and analysis. Our award-winning team covers news on Wall Street, policy developments in Washington, early science breakthroughs and clinical trial results, and health care disruption in Silicon Valley and beyond.